TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 ...

Based on both its mechanism of action and strong preclinical profile, we believe TVB-3567 has the potential to offer a differentiated treatment option for acne. We look forward to initiating ...

Based on both its mechanism of action and strong preclinical profile, we believe TVB-3567 has the potential to offer a differentiated treatment option for acne. We look forward to initiating ...

Sagimet Biosciences (SGMT) announced the clearance of its Investigational New Drug, IND, application for TVB-3567, the Company’s second fatty ...

TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences ...

Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today ...

Join Dr. Dustin, a board-certified dermatologist, as he delves into how birth control pills can effectively treat acne. This video elucidates the mechanisms behind birth control's impact, such as ...

Prime Biome is a recently launched dietary gummy designed to target both skin and gut in one go. It uses potent ingredients ...

Discover ways reducing sugar intake benefits your body and mind, from diminishing belly fat and improving skin to enhancing ...

and flaring of acne. Because of the risk of teratogenicity, women of childbearing age must not become pregnant while exposed to isotretinoin. The mechanism of action of isotretinoin is not ...